Replimune Group price target raised to $12 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Replimune Group to $12 from $10 and keeps a Buy rating on the shares following the fiscal Q3 report. The firm increased its forecasted duration of treatment for RP1 to 12 months from the prior eight months and raised the discount rate to 11% from 10%.